Rivera v. Commissioner of Social Security

CourtDistrict Court, E.D. New York
DecidedApril 21, 2023
Docket1:20-cv-05501
StatusUnknown

This text of Rivera v. Commissioner of Social Security (Rivera v. Commissioner of Social Security) is published on Counsel Stack Legal Research, covering District Court, E.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Rivera v. Commissioner of Social Security, (E.D.N.Y. 2023).

Opinion

UNITED STATES DISTRICT COURT EASTERN DISTRICT OF NEW YORK ------------------------------------x

JAHMEL RIVERA,

Plaintiff, MEMORANDUM & ORDER 20-CV-5501 (EK)

-against-

COMMISSIONER OF SOCIAL SECURITY,

Defendant.

------------------------------------x ERIC KOMITEE, United States District Judge: Plaintiff Jahmel Rivera challenges the Social Security Administration’s denial of his claim for disability benefits. Before the Court are the parties’ cross-motions for judgment on the pleadings. Rivera argues that the agency’s decision is not supported by substantial evidence and that the administrative law judge committed legal error by failing to account adequately for, and develop the record on, his seizure disorder. For the following reasons, this case is remanded for further proceedings. I. Background A. Procedural Background In July 2017, Rivera applied for benefits, alleging a disability onset date of January 1, 2016. Administrative Tr. (“Tr.”) 15, ECF No. 9. The agency denied his claim. Id. at 12. On December 5, 2019, an administrative law judge held a hearing on Rivera’s claim. Id. at 15. The ALJ concluded that Rivera was not disabled and therefore not entitled to disability benefits. Id. at 23. The Appeals Council denied Rivera’s request for review of the ALJ’s decision, rendering it final. Id. at 1. Rivera timely sought review of that decision in this

Court. B. Evidence of Rivera’s Seizure Disorder 1. Rivera’s Testimony Before the ALJ At the hearing before the ALJ in December 2019, Rivera testified that he had petit mal seizures “approximately four times per week” — “[s]ometimes more,” but “never less.” Id. at 39.1 He stated that the seizures cause him to feel weak and dizzy and leave him unable to stand. Id. The seizures themselves typically last between one and five minutes, but the symptoms last longer: approximately from forty-five minutes to twenty-four hours. Id. at 39-40. During the symptomatic period, Rivera testified, he is “incoherent” and “can’t really

do much more than” sit down. Id. at 40. Rivera also testified that the dosage of his then-current prescription medication (oxcarbazepine) had increased over time, and that the side effects included feeling “dull” or “not as sharp.” Id. at 41.

1 A petit mal seizure, or “absence” seizure, involves the disturbance of brain function and causes staring spells. See Def. Mem. in Supp. of Cross- Mot. for Summ. J. 2 n.2, ECF No. 16-1. Moreover, he explained that while working his prior job as a retail manager, he “didn’t know when [he] would have a seizure,” and when a seizure did occur, he would miss work or arrive late. Id. at 36, 43. Because those attendance issues resulted in “a lot of disciplinary action,” he ultimately decided that he “had

to quit.” Id. at 43. 2. Rivera’s Medical Records Rivera’s medical records show that he suffered recurring seizures between 2017 and 2019.2 In January 2017, Marissa Modafferi — a physician assistant who had treated Rivera since 2011 — noted that Rivera reported “having more seizures and many breakthrough[s]” even while on a daily medication regimen of three doses of oxcarbazepine (600 milligrams in the morning and midday and 300 milligrams in the evening). Id. at 354.3 In response, Modafferi increased the doses such that he would take 900 milligrams in the morning, 600 milligrams midday, and 900 milligrams in the evening. Id. at 354-55. Rivera had

suffered “no adverse side effects” on the prior, lower-dose

2 The medical records indicate that Rivera had a multi-year period — lasting approximately from 2012 until at least June 2016 — without seizures. See id. at 361 (May 2015 report: Rivera’s “last seizure was about three years ago”); id. at 360 (December 2015 report: Rivera “is having no breakthrough seizures”); id. (June 2016 report: Rivera had “[n]o breakthrough seizures or grand mal seizures”). 3 The earliest report by Modafferi is dated July 7, 2011 and describes the visit as a “follow up.” Id. at 367-68. Each of Modafferi’s reports also contains the name of Dr. Stephen Kulick, M.D. See, e.g., id. regimen. Id. at 354. Six months later, in July 2017, Modafferi noted that Rivera “is not missing any doses of medication” but nevertheless has “had a couple of breakthrough absence seizures.” Id.4 Modafferi’s 2018 reports similarly documented

instances of recurring seizures even as Rivera maintained the same medication regimen. In March 2018, Rivera reported having “a couple of petit mal seizures” while still taking 900 milligrams of oxcarbazepine twice per day and 600 milligrams once per day. See id. at 417.5 At that time, Rivera expressed interest in trying Oxtellar, a different epilepsy medication with an “extended release.” Id. at 415. In September 2018, however, Modafferi explained that Rivera had “tried switching to Oxtellar,” but that “he felt anxious on it and decided to stick with oxcarbazepine instead.” Id. Modafferi also recorded that, while Rivera “continues to remain stable” on the oxcarbazepine regimen, he nonetheless “continues to suffer from petit mal

seizures about 3-4 [times] a week which he is accepting at this time.” Id.

4 Modafferi’s report states that Rivera was taking Oxtellar at that point, see id. at 354, but Rivera’s “Current Medication List” shows that he was still taking oxcarbazepine as of July 31, 2017. See id. at 349. Moreover, the notes from Rivera’s March 2017 EEG monitoring show that he was taking oxcarbazepine at that time. See id. at 419. Thus, the reference to Oxtellar in Modafferi’s report appears to be a mistake. 5 This report did not specify how often or over what period Rivera had those seizures. Rivera’s seizures persisted throughout 2019 as he remained on the same medication regimen. In a March 2019 report, Modafferi noted that Rivera “continue[s] to have some petit mal seizures on occasion” but “remain[s] stable” on the oxcarbazepine regimen. Id. at 413. Per the report, Rivera

stated that “some days he would forget to take the afternoon dosage,” but Modafferi did not address the extent to which those lapses may have contributed to his seizures. Id. The report went on to note that Rivera agreed to switch his medication to Oxtellar again. Id. at 413-414. But after Rivera’s follow-up visit in October 2019, Modafferi wrote in her report (the most recent medical report in the record as of Rivera’s hearing) that Rivera had “decided to hold off” on Oxtellar and “continue on his current regimen” of oxcarbazepine. Id. at 411. She stated that Rivera “remain[s] stable” on the oxcarbazepine regimen. Id. During that visit, Modafferi found that Rivera’s condition was much the same as it had been in March. She again noted that

Rivera “continue[s] to have some petit mal seizures.” Id. at 411. Modafferi added, however, that “for the most part [the seizures] are under control.” Id.6 “[T]herefore,” she stated, Rivera’s treatment would continue “without change.” Id.

6 Modafferi offered no explanation for this assertion. C. The ALJ’s Disability Evaluation Under the Social Security Act, “disability” is defined as the “inability to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment . . . which has lasted or can be expected to last for

a continuous period of not less than 12 months.” 42 U.S.C. § 423(d)(1)(A). The Social Security Administration’s regulations require ALJs to follow a five-step sequence in evaluating disability claims. 20 C.F.R. § 404.1520(a)(4). First, the ALJ determines whether the claimant is engaged in substantial gainful activity. Id. § 404.1520(a)(4)(i), (b).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Burgess v. Astrue
537 F.3d 117 (Second Circuit, 2008)
Mancuso v. Astrue
361 F. App'x 176 (Second Circuit, 2010)
Moran v. Astrue
569 F.3d 108 (Second Circuit, 2009)
Mathews v. Barnhart
220 F. Supp. 2d 171 (W.D. New York, 2002)
Fiedler v. Colvin
54 F. Supp. 3d 205 (E.D. New York, 2014)
Hooper v. Colvin
199 F. Supp. 3d 796 (S.D. New York, 2016)

Cite This Page — Counsel Stack

Bluebook (online)
Rivera v. Commissioner of Social Security, Counsel Stack Legal Research, https://law.counselstack.com/opinion/rivera-v-commissioner-of-social-security-nyed-2023.